Gopakumar V Iyer

34PUBLICATIONS
293CO-AUTHORS
Molecular targetsCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Aug 27, 2026
A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.

|Feb 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial.

Matthew D Galsky, Charlene Mantia, Michaela Bowden

|Feb 09, 2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.

Andrew B Katims, Charlie White, Syed Muneeb Alam

|Feb 02, 2026
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran

|Dec 20, 2025
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer.

Ziyu Chen, Xinran Tang, Jordan E Eichholz

|Jul 01, 2025
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.

Gopa Iyer, Woonyoung Choi, Bin Luo

Pageof 6

Frequent Collaborators

16 joint publications

Hikmat Al-Ahmadie

15 joint publications

David Solit

10 joint publications

Samuel Funt

10 joint publications

Jonathan E Rosenberg